We believe our work at SYNSIGHT goes towards exploiting the tools of modern biology to generate qualitative data sets rather than relying on existing but unreliable data.
The company develops a screening technology that enables the development of effective First in Class drug candidates based on a discovery platform to the convergence of artificial intelligence and cell imaging.
We developed a platform that benefits from new technologies that have been widely developed in recent years : AI, cellular imaging, robotization.
The convergence of these technologies and the close collaboration of data scientists and biologists make it possible to create biological models of very large size and significance
GET IN TOUCH
We will get back to you as soon as possible
4 rue Pierre Fontaine